Asian Spectator

.
Commercial Property

.

ECOVACS Reimagines the Future of Home Cleaning with the launch of an Extensive Range of Innovative Products Designed for City Dwellers

ECOVACS unveils two new robotic vacuums - the DEEBOT T30 PRO OMNIand DEEBOT X2 COMBO - specially designed to tackle cleaning challenges faced by city dwellers First 100 customers to purcha...

World's first C919 Aircraft delivered to China Eastern Airlines

SHANGHAI, Dec. 12, 2022 /Xinhua-AsiaNet/-- On Dec. 9, the world's first C919 aircraft, with registration number of B-919A, was delivered to its world's first launch customer, China Eastern A...

Lenovo Expands Portfolio of Smart Collaboration Solutions With New Standalone ThinkSmart View Plus

ThinkSmart View Plus running Microsoft Teams display allows users to better collaborate in multiple scenarios with a dedicated unified video communications solution. New Lenovo I...

NSO Group Responds to Ongoing False Forbidden Stories Allegations

TEL AVIV, Israel, July 22, 2021 /PRNewswire-AsiaNet/ -- Attributable to an NSO Spokesperson -"Enough is enough!"In light of the recent planned and well-orchestrated media campaign lead by Fo...

New Philips Monitor is Released with SuperWide Docking Monitor with Noise-Canceling 5MP Webcam

SINGAPORE - Media OutReach - 4 April 2023 - This monitor combines two desktops and a webcam in one setup. On [4th April 2023], the new Philips monitor, 45B1U6900CH, will be available to th...

InsureTech Connect Experience Expanding to Asia

SINGAPORE / NEW YORK, NY, Aug 29, 2019 - (ACN Newswire) - Today, InsureTech Connect ("ITC") is proud to officially announce the launch of ITC Asia, taking place the 2nd-4th June 2020 in Sin...

iChongqing: Public Art into Life, Make Art Live in Nature

CHONGQING, China, Nov. 20, 2018 /PRNewswire-AsiaNet/ -- This article was written by Rui Hu for iChongqing: On 18 November 2018, Yuelai Public Art Exhibition themed with signs, symbols, and r...

Kaohsiung Draws Potential Investors at Kumamoto Expo

KAOHSIUNG, TAIWAN - Media OutReach Newswire - 4 March 2024 - Headed by Deputy Mayor Lo Ta-sheng, the Kaohsiung delegation to KUMAMOTO Industrial Revitalization EXPO 2024 and for a fact-find...

Village House’ Multilingual Support Team Ensures a Smooth Move for Vietnamese Living in Japan

Village House enhances its multilingual support service, extending its reach to Vietnamese workers in Japan. As of June 2021, Village House provides more support to those who want to find a ...

Israeli Biotech SuperTrans Medical Announces $2 Million Strategic Investment from South Korean Mediforum

Israeli Biotech SuperTrans Medical Announces $2 Million Strategic Investment from South Korean Mediforum

Tel Aviv, Israel, Apr 7, 2020 - (ACN Newswire) - via NEWMEDIAWIRE -- SuperTrans Medical ("SuperTrans"), a privately held biopharmaceutical company with initial focus on the discovery and development of novel antibiotics, today announced that leading South Korean biopharma Mediforum Pharm (KOSDAQ: 047920) will make a $2M investment in SuperTrans. In return, Mediforum will collaborate with SuperTrans in the manufacturing and commercialization of SuperTrans' products in Asia, including South Korea, China, and Japan. Additionally, Mediforum will fully commit and support SuperTrans' future drug development programs.

The SuperTrans technology was discovered by chemists Prof. Paul A Wender (Professor of Chemistry, School of Humanities and Sciences, and by courtesy, of Chemical and Systems Biology Stanford Medical School, Stanford University) and Prof. Lynette Cegelski (Professor of Chemistry, School of Humanities and Sciences), both on the Scientific Advisory Board of the company. Professor Wender's guanidinium-rich, molecular transporter technology, inspired by nature, is licensed from Stanford University by SuperTrans Medical and its partner, Mediforum. This technological approach could help bridge a gap to deliver urgently needed antibiotics to thwart multi-drug resistant bacterial pathogens.

In addition, SuperTrans is completing candidate assessments for the treatment of COVID-19 based on its transporter technology. The candidate compound will be aimed in preventing both viral and bacterial pulmonary infections. The company is currently preparing its drug development program.

SuperTrans Medical's R&D team consists of individuals from Major Pharma' with drug development successes, including antibiotics and HIV inhibitors. These are Dr. Lewis Neville, CEO, Dr. Jacob Rendell, CTO (Ex-Teva), Dr. Patricia Bradford (Ex-Wyeth, Novartis and AstraZeneca), Dr. Joseph Vacca (Ex-Merck and WuXi Apptec), Dr. Peter Warn (Ex-Evotec) and Prof. Itamar Shalit, a pediatric clinical infectious diseases specialist.

Mediforum is a Seoul-based pharmaceutical company which is specialized for researching and developing novel drugs against neuro-degenerative disease such as Alzheimer's disease and Parkinson's disease. "SuperTrans Medical is thrilled to partner with Mediforum as our lead strategic investor. We are looking forward to a long-term partnership to further develop and commercialize the SuperTrans technology," commented Lewis F. Neville, CEO of SuperTrans Medical. "In a short period of time, we have made significant inroads into the design and evaluation of different FDA-approved antibiotics that were conjugated to the company's unique transporter technology. This has already resulted in the identification of a number of compounds worthy of late stage development. Mediforum has identified the strength of our platform technology to improve the properties of existing FDA-approved antibiotics. Mediforum's investment will allow a lead antibiotic-conjugate to enter Phase 1 testing within 12-15 months."

"We are delighted to invest in SuperTrans. We have been impressed by their rapid progress during the last number of months that has culminated in the development of a number of lead compounds. We believe that their transporter technology can represent a paradigm-shift for the accelerated development of much needed antibiotics into human trials. Mediforum will proactively play its role as a strategic partner through the co-exchange of all research and development efforts. Although SuperTrans' technology is at a relatively early stage of development, we anticipate the launch of a new generation antibiotic for testing will be relatively fast. This is because the technology can be easily conjugated to existing FDA-approved antibiotics," commented Mr. Park Jaehyung, CEO of Mediforum. "Furthermore, SuperTrans is strengthening its pipeline through its support of Stanford University and other scholars. Also, SuperTrans is preparing for a Hong Kong IPO in 2022, which is highly attractive for Mediforum," further commented Mr. Park Jaehyung.

About SuperTrans Medical

SuperTrans Medical is a biopharmaceutical company developing novel antibiotics by improving the properties of existing, FDA compounds following chemical conjugation to a unique transporter technology called Guanidinium-Rich Molecular Transporter (GRMoTr). A main obstacle in the development of effective antibiotics is to effectively overcome the structural complexities of the outer bacterial membrane. This is particularly pertinent for Gram-negative bacteria. The GRMoTr bestows upon antibiotics, a vastly improved capability to breach the outer membrane and effectively eradicate Gram-positive and Gram-negative pathogens including multi-drug resistant strains.

About Mediforum

Mediforum Pharm is a brain healthcare specialized pharmaceutical company that discovers and develops treatment for degenerative brain diseases such as Alzheimer's and Parkinson's diseases among others. Currently, the company is aggressively expanding its R&D pipeline together with its rapidly growing prescription drug sales. Furthermore, Mediforum is actively engaging with overseas research institutes in order to expand operations beyond domestic borders and penetrate the global market.

For more information, contact:Lewis F. Neville, PhDCEOSuperTrans Medicallewis@supertransmedical.com

Eran GilboaCFOSuperTrans Medicaleran@supertransmedical.com

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Dampak penyebaran teror: bagaimana ketakutan mengubah pikiran kita

Anas-Mohammed/ShutterstockPada Mei 1097, tentara salib melemparkan kepala-kepala tahanan yang dipenggal ke atas tembok Nicaea, Turki. Tujuan dari aksi ini adalah untuk meneror para pembela dan menaklu...

Apakah memiliki anak membuatmu lebih bahagia? Ini kata penelitian

The happiness and fulfilment you feel with the decision will depend on many different factors.CeltStudio/ ShutterstockKepercayaan yang berkembang di berbagai belahan dunia adalah bahwa memiliki anak a...

Cek Fakta: Prabowo mengklaim rasio pajak Indonesia di bawah negara tetangga. Benarkah?

Ekie E Sularso/Shutterstock‘Tax ratio’ kita banyak bisa di-‘improve’ sekarang 10% dan tetangga kita di 16%, Thailand Malaysia 16%, Vietnam-Kamboja sekitar 16%, 17%, 18%.–...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion